Navigation Links
Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Date:5/11/2009

he Phase 2b with Roche in second half of 2009;
  • Report phase 1 antiviral data with PSI-7851 in second half of 2009;
  • Report further data from INFORM-1 trial in fourth quarter of 2009.

  • About Pharmasset

    Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

    Pegasys(R) and Copegus(R) are registered trademarks of Roche.

        Contact
        Richard E. T. Smith, Ph.D.
        VP, Investor Relations and Corporate Communications
        richard.smith@pharmasset.com
        Office: +1 (609) 613-4181
    

    Forward-Looking Statements

    Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any
    '/>"/>

    SOURCE Pharmasset, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
    3. Pharmasset Accesses up to $30 Million of Working Capital
    4. Pharmasset to Present at Three Investor Conferences in November 2007
    5. Pharmasset Appoints Michael Rogers as Chief Development Officer
    6. Pharmasset Reports Fiscal Year End 2007 Financial Results
    7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
    8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
    9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
    10. Pharmasset Appoints Herbert J. Conrad as a Director
    11. Pharmasset Receives $10 Million of Working Capital
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... It’s a hard truth: Nearly half of recent veterans who ... are failing to obtain a diploma or certificate within a ... an analysis by The Resume Place , a major ... college majors, which leads to underemployment, unemployment or just plain ... of post-9/11 veterans using GI Bill education benefits ...
    (Date:7/28/2014)... DUBLIN , July 28, 2014 Research ... "Global Particle Size Analysis Market 2014-2018" report to their ... Particle size analysis is a technique used to determine ... powder or liquid. It is crucial to analyze the size ... material. Therefore, particle size analysis is performed to determine the ...
    (Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
    (Date:7/25/2014)... July 25, 2014 According to a ... Drugs Market - Global Industry Analysis, Size, Share, Growth, ... drugs market is estimated at USD 161,056.5 million in ... of 10.1% from 2014 to 2020, to reach an ... The biological drugs market is witnessing a significant growth ...
    Breaking Biology Technology:Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Particle Size Analysis Market 2014-2018 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
    ... Registry reveals that 70% of deaths in the stable stroke ... other than stroke, NICE, France, May 15 New ... Congress, highlight that among,those who die after a stroke the ... overall death rate is 4.45%, with,3.23% of these CV deaths ...
    ... , Chinese researchers have recently made a golden ... is a large ring-shaped molecule containing 36 gold atoms. The ... Universities of Beijing, Hong Kong, and Nanjing report their unusual ... is held together exclusively by goldgold bonds and is thus ...
    ... opportunities for micro and nano technologies. These challenges are ... the control and understanding of their behaviour. , This ... fibre analysis at the micro and nano-scale using state-of-the ... techniques. , Topics include fundamental effects of topography in ...
    Cached Biology Technology:Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 2Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 3Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 4Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5Golden nanocrown 2Micro and Nano Scale Characterization of Fibers 2
    (Date:7/28/2014)... suggests that the effects of a commonly used anesthetic ... , The study, published in this week,s issue of ... biologists at the University of California, San Diego and ... to concerns, arising from multiple studies on humans over ... may increase their susceptibility to long-term cognitive and behavioral ...
    (Date:7/28/2014)... identified areas of the Earth that are high priorities ... Europe is particularly vulnerable, as it has the lowest ... of any continent in ,refugia, areas of biological ... remain relatively constant during times of great environmental change. ... in Scandinavia and Scotland. , The biggest refugia ...
    (Date:7/28/2014)... that can help advance the genetic engineering of ... has been developed by researchers with the U.S. ... a multi-institutional partnership led by Lawrence Berkeley National ... an assay that enables scientists to identify and ... components in the biosynthesis of plant cell walls. ...
    Breaking Biology News(10 mins):Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2How sweet it is 2How sweet it is 3
    ... aspires to a lifetime of addiction. But their brains ... journal Neuropsychopharmacology this week, Rockefeller University researchers ... can sustain lifelong and permanent changes in their reward ... and make such adolescents more vulnerable to the drug,s ...
    ... of Palm Vein Authentication Technology with, Single-Sign On Solutions ... ... Passwords, SUNNYVALE, Calif., Sept. 9 Fujitsu Computer ... products including,hard disk drives, peripherals and biometric security solutions, ...
    ... novel way to improve survival and recovery rate after ... Stem Cell Research by scientists at Singapore,s Institute ... and The Netherlands, University Medical Center Utrecht. ... the first non-cell based therapeutic application of human embryonic ...
    Cached Biology News:Abuse of painkillers can predispose adolescents to lifelong addiction 2Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR 2Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR 3Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR 4Human embryonic stem cell secretions minimized tissue injury after heart attack 2Human embryonic stem cell secretions minimized tissue injury after heart attack 3
    EML1 (K-16)...
    Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
    Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
    ... ,• Eliminates nonspecific products due to ... specificity allows extension through DNA regions which ... Leaves an 'A' overhang ,TEMPase II ... DNA Polymerase that remains inactive at ...
    Biology Products: